Octreotide as first-line treatment for women with metastatic breast cancer

James N. Ingle; Carl G. Kardinal; Vera J. Suman; James E. Krook; Alan K. Hatfield

doi:10.1007/BF00210797

Octreotide as first-line treatment for women with metastatic breast cancer

James N. Ingle, Carl G. Kardinal, Vera J. Suman, James E. Krook, Alan K. Hatfield

Research output: Contribution to journal › Article › peer-review

15 Scopus citations

Abstract

Octreotide is a synthetic somatostatin analogue which has shown inhibitory activity against human breast cancer cells in culture. Ten patients with metastatic breast cancer and no prior hormonal therapy exposure received octreotide at 150 μg subcutaneously thrice daily. No objective responses were observed and the median time to treatment failure was short at 57 days.

Original language	English (US)
Pages (from-to)	235-237
Number of pages	3
Journal	Investigational New Drugs
Volume	14
Issue number	2
DOIs	https://doi.org/10.1007/BF00210797
State	Published - 1996

Keywords

Metastatic breast cancer
Octreotide

ASJC Scopus subject areas

Oncology
Pharmacology
Pharmacology (medical)

Access to Document

10.1007/BF00210797

Cite this

@article{e803b41728d24b9a87b2f325643d3098,

title = "Octreotide as first-line treatment for women with metastatic breast cancer",

abstract = "Octreotide is a synthetic somatostatin analogue which has shown inhibitory activity against human breast cancer cells in culture. Ten patients with metastatic breast cancer and no prior hormonal therapy exposure received octreotide at 150 μg subcutaneously thrice daily. No objective responses were observed and the median time to treatment failure was short at 57 days.",

keywords = "Metastatic breast cancer, Octreotide",

author = "Ingle, {James N.} and Kardinal, {Carl G.} and Suman, {Vera J.} and Krook, {James E.} and Hatfield, {Alan K.}",

year = "1996",

doi = "10.1007/BF00210797",

language = "English (US)",

volume = "14",

pages = "235--237",

journal = "Investigational New Drugs",

issn = "0167-6997",

publisher = "Kluwer Academic Publishers",

number = "2",

}

TY - JOUR

T1 - Octreotide as first-line treatment for women with metastatic breast cancer

AU - Ingle, James N.

AU - Kardinal, Carl G.

AU - Suman, Vera J.

AU - Krook, James E.

AU - Hatfield, Alan K.

PY - 1996

Y1 - 1996

N2 - Octreotide is a synthetic somatostatin analogue which has shown inhibitory activity against human breast cancer cells in culture. Ten patients with metastatic breast cancer and no prior hormonal therapy exposure received octreotide at 150 μg subcutaneously thrice daily. No objective responses were observed and the median time to treatment failure was short at 57 days.

AB - Octreotide is a synthetic somatostatin analogue which has shown inhibitory activity against human breast cancer cells in culture. Ten patients with metastatic breast cancer and no prior hormonal therapy exposure received octreotide at 150 μg subcutaneously thrice daily. No objective responses were observed and the median time to treatment failure was short at 57 days.

KW - Metastatic breast cancer

KW - Octreotide

UR - http://www.scopus.com/inward/record.url?scp=0029818962&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029818962&partnerID=8YFLogxK

U2 - 10.1007/BF00210797

DO - 10.1007/BF00210797

M3 - Article

C2 - 8913847

AN - SCOPUS:0029818962

SN - 0167-6997

VL - 14

SP - 235

EP - 237

JO - Investigational New Drugs

JF - Investigational New Drugs

IS - 2

ER -

Octreotide as first-line treatment for women with metastatic breast cancer

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this